Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis Ord (STXS) delivers pioneering robotic solutions for cardiac arrhythmia treatment and complex vascular procedures. This page serves as the definitive source for official company news, providing investors and healthcare professionals with timely updates on innovations shaping the future of interventional medicine.
Access curated press releases and announcements covering regulatory milestones, product launches, and strategic partnerships. Our repository ensures you stay informed about developments in robotic navigation systems and integrated healthcare technologies without speculative commentary.
Key updates include earnings reports, FDA clearances, clinical trial outcomes, and technological advancements in electrophysiology. Bookmark this page for direct access to Stereotaxis' verified communications, enabling informed analysis of their market position in medical robotics sector.
Stereotaxis (STXS) reported a second quarter 2022 revenue of $6.2 million, down from $9.1 million in Q2 2021, driven by reduced system sales. Operating loss and net loss for the quarter were approximately ($5.2 million), compared to ($3.4 million) and ($1.2 million) the previous year. The company noted a strong gross margin of 76%, with recurring revenue gross margin at 83%. Despite financial challenges, Stereotaxis is advancing its innovation pipeline, with three new orders for Genesis systems and plans for future product launches.
Stereotaxis (NYSE: STXS) announced enhancements to its commercial leadership team with two experienced executives, Frank Van Hyfte and Tim Glynn. Van Hyfte will serve as VP for Europe, the Middle East, and Africa, bringing over 15 years of experience from Intuitive Surgical. Glynn joins as VP of Market Development, previously with Acutus Medical. Both leaders aim to increase commercial growth and build a robust product ecosystem for Stereotaxis, which specializes in robotic technologies for minimally invasive endovascular procedures.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced the release of its financial results for Q2 2022 on August 9, 2022, prior to market open. The company will host a conference call at 10 a.m. ET to discuss its financial performance and corporate developments. Stereotaxis aims to enhance patient care through advanced robotic systems, having treated over 100,000 patients globally.
Stereotaxis (STXS) announced the CE Mark submission for its MAGiC™ catheter, a robotically navigated device for cardiac ablation. This innovation aims to enhance precision and safety in treating cardiac arrhythmias. Developed with Osypka, the MAGiC catheter builds on nearly 20 years of experience and over 100,000 procedures. Following CE Mark approval, Stereotaxis plans to launch the catheter commercially in Europe by year-end. The company is also preparing for FDA submission for a U.S. trial. This marks a significant milestone for Stereotaxis and the robotic electrophysiology field.
Stereotaxis (NYSE: STXS) announced the publication of a special issue in the Journal of Atrial Fibrillation & Electrophysiology on Robotic Magnetic Navigation (RMN) for cardiac arrhythmias. The issue features 16 peer-reviewed studies, contributed by physicians from 20 hospitals worldwide, highlighting RMN's clinical benefits. Key topics include the history of RMN, successful patient outcomes, fluoroscopy-free procedures, and advancements in robotic technology. This collaboration aims to enhance awareness and education in electrophysiology, emphasizing the growing importance of robotics in treating arrhythmias.
Stereotaxis (STXS) reported Q1 2022 revenue of $7.0 million, down from $8.6 million in Q1 2021, with system revenue at $1.6 million and recurring revenue at $5.4 million. The gross margin is approximately 70%, with recurring revenue gross margin at 85%. Operating loss increased to ($4.1 million) from ($1.5 million) last year. The company has a cash balance of $36.9 million as of March 31, 2022, with no debt. Despite challenges, Stereotaxis anticipates ongoing revenue growth driven by innovations and capital adoption.
Stereotaxis (NYSE: STXS) announced it will release its 2022 first quarter financial results on May 10, 2022, before U.S. markets open. The company will host a conference call at 10 a.m. EST to discuss the results and corporate developments. Investors can access the call at 888-254-3590 (US) or 1 929-477-0448 (International) using passcode 5168103. A replay will be available for one month after the call. Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 100,000 patients globally.
Stereotaxis (NYSE: STXS) announces that Poland's National Institute of Cardiology has launched the first robotic electrophysiology program using the Genesis Robotic Magnetic Navigation (RMN) system, enhancing cardiac arrhythmia treatment. This technology is now operational in 25 countries. A study reports that 3.8% of Warsaw residents aged 20-65 have arrhythmias, indicating over 2 million potential cases in Poland. This initiative aims to improve patient care and advance clinical science in Europe.
Stereotaxis (NYSE: STXS) has inaugurated its new 45,000-square-foot global headquarters in downtown St. Louis, located in the historic Globe Building. This state-of-the-art facility will significantly enhance its surgical robotics operations for minimally invasive endovascular interventions. The headquarters is designed for substantial long-term growth, housing R&D, advanced manufacturing, and distribution capabilities. The event featured demonstrations of their Robotic Magnetic Navigation technology, which has been utilized in over 100 hospitals worldwide.
FAQ
What is the current stock price of Stereotaxis Ord (STXS)?
What is the market cap of Stereotaxis Ord (STXS)?
